ESC 365 - Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

HFA Premium Access

Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

Session: Heart failure with preserved ejection fraction (HFpEF) 3

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor J. Ostrominski (Boston, US)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

0 follower

4 more presentations in this session

Maximal functional capacity response to physical therapies according to ferrokinetics in heart failure with preserved ejection fraction. A substudy of the training-hf trial

Speaker: Doctor P. Palau Sampio (Valencia, ES)

A ventricular conduction delay phenotype and its outcome in heart failure with preserved ejection fraction

Speaker: Ms A. Achten (Maastricht, NL)

Invasive validation of H2FPEF score for diagnosis of heart failure with preserved ejection fraction (HFpEF)

Speaker: Doctor M. Podolec (Prague, CZ)

Retinal neurovascular changes in heart failure with preserved ejection fraction: an optical coherence tomography angiography pilot study

Speaker: Mr J. Weerts (Maastricht, NL)

Access the full session

Heart failure with preserved ejection fraction (HFpEF) 3

Speakers: Doctor J. Ostrominski, Doctor P. Palau Sampio, Ms A. Achten, Doctor M. Podolec, Mr J. Weerts

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources